Sun et al. (2017) demonstrated that certain PSEN1 mutations alter γ-secretase activity, with varying effects on Aβ production, highlighting the need to consider mutation-specific variability when exploring γ-secretase modulation in AD therapies [41]. This evidence concerns the gene PSEN1 and Alzheimer disease.